Last reviewed · How we verify
NCT05801198
Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.
Phase 2 trial testing Artemisia afra or Annua 10g oral infusion/tea per day for 14 days in Malaria,Falciparum in 125 participants. Not yet recruiting.
30 April 2026
Quick facts
| Lead sponsor | King Faisal Hospital Rwanda |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 125 |
| Start date | 1 March 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Artemisia afra or Annua 10g oral infusion/tea per day for 14 days
Conditions studied
- Malaria,Falciparum — all drugs for Malaria,Falciparum →
Sponsor
King Faisal Hospital Rwanda
Who can join
Adults 18 to 65, any sex, with Malaria,Falciparum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators believe that to effectively achieve malaria elimination in Rwanda, it is critical to target the human reservoirs of Plasmodium falciparum using local and readily available Artemisia tea. Asymptomatic infections detectable by PCR are important reservoirs because they often persist for months and harbor gametocytes, the parasite stage infectious to mosquitoes. Lessons learnt from this study will be of critical importance for health decision makers with regard to potential malaria control. MSc and PhD students will be trained and the impact of this research project will be enormous on the socioeconomic transformation of Rwanda.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05801198
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malaria,Falciparum
Currently open trials in the same condition.
- NCT06618885 — Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso · Phase 1 · active not recruiting
- NCT07009847 — An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine · recruiting
- NCT06524336 — Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children · active not recruiting
- NCT05978037 — A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines · Phase 1, PHASE2 · active not recruiting
- NCT05790889 — A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05801198 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King Faisal Hospital Rwanda
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05801198.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing